Evidence map›Paper›PMID 41255978›Full record

ArticleResearch square2025

Integrated Multiclass Driver ctDNA Profiling Enables MPNST Detection and Monitoring in NF1 Patients.

Paul A Jones, Aaron U Bektas, Jeffrey J Szymanski, R Taylor Sundby, John S A Chrisinger, Peter K Harris, Mark I Zoberi, Kara Weekley, Sanita Burgic, Stacey Chamberlain and 4 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Paul A JonesWashington University School of Medicine.
Aaron U BektasWashington University School of Medicine.
Jeffrey J SzymanskiMayo Clinic.
R Taylor SundbyNemours Children's Health, Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders.
John S A ChrisingerWashington University School of Medicine.
Peter K HarrisWashington University School of Medicine.
Mark I ZoberiWashington University School of Medicine.
Kara WeekleyWashington University School of Medicine.
Sanita BurgicWashington University School of Medicine.
Stacey ChamberlainWashington University School of Medicine.
Faridi QaiumMayo Clinic.
Jack F ShernNational Cancer Institute, National Institutes of Health.
Aadel A ChaudhuriMayo Clinic.
Angela C HirbeWashington University School of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed and cross-validated an integrated circulating tumor DNA assay incorporating SNVs, indels, CNAs, and SVs to distinguish neurofibromatosis type 1 patients with malignant peripheral nerve sheath tumors from those with benign plexiform neurofibromas or tumor-free controls. Among 82 participants, the assay achieved an AUC of 0.904, compared with 0.735 for genome-wide CNAs. We also detected recurrent disease-specific driver alterations, relapse up to three months before diagnosis, and early clearance consistent with durable remission.

Identifiers

PMID41255978
PMCPMC12622166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.